russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2020-4024russjcardiol-4024Research ArticleСТАТЬИARTICLESНаследственная тромбофилия и венозные тромбоэмболические осложнения: правила тестирования в клинической практикеInherited thrombophilia and venous thromboembolism: testing rules in clinical practicehttps://orcid.org/0000-0001-8309-8231ЗотоваИ. В.ZotovaI. V.

к.м.н., доцент, кафедра терапии, кардиологии и функциональной диагностики с курсом нефрологии, врач-кардиолог

Москва, 121359, ул. Маршала Тимошенко д.19, с.1А

Москва 119620 ул. Волынская 7

PhD, MD, fssociate professor, Department of therapy, cardiology and functional diagnostics with the course of nephrology

M. Timoshenko str, 21, 121359 Moscow

Volynskaya str, 7, 119620 Moscow

irinazotova@bk.ruhttps://orcid.org/0000-0001-7065-2045ЗатейщиковД. А.ZateyshchikovD. A.

д.м.н., профессор, зав. кафедрой терапии, кардиологии и функциональной диагностики с курсом нефрологии, заведующий первичным сосудистым отделением

Москва, 121359, ул. Маршала Тимошенко д.19, с.1А

Москва 121309, ул. Алябьева д7/33

PhD, MD, Professor, Head department of therapy, cardiology and functional diagnostics with a course of nephrology, Head of the primary vascular department

M. Timoshenko str, 21, 121359 Moscow

Alyabeva str, 7/33, 121309 Moscow

dz@bk.ruФГБУ ДПО "Центральная государственная медицинская академия" Управления делами Президента РФ; ГБУЗ Городская клиническая больница № 17 Департамента здравоохранения города МосквыРоссияCentral State Medical Academy, Administrative Directorate of the President of the Russian Federation; City Clinical Hospital № 17Russian FederationФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента РФ; ГБУЗ Городская клиническая больница № 51 Департамента здравоохранения города МосквыРоссияCentral State Medical Academy, Administrative Directorate of the President of the Russian Federation; City Clinical Hospital № 51Russian Federation202017072020253S3S40244024Copyright © Зотова И.В., Затейщиков Д.А., 20202020Зотова И.В., Затейщиков Д.А.Zotova I.V., Zateyshchikov D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/4024

Тестирование на наследственную тромбофилию пациентов с венозными тромбоэмболическими осложнениями является одним из самых частых вариантов генетического анализа, назначаемого клиницистами. Несмотря на большую доказательную базу связи наследственных нарушений в системе гемостаза с риском развития венозных тромбозов, большинство пациентов не должно подвергаться тестированию. Выполнение ряда тестов в остром периоде тромбоза или на фоне лечения антикоагулянтами приводит к ошибочным результатам. Выбор режима антикоагулянтной терапии и ее продолжительность не определяются фактом наличия наследственной тромбофилии. Результаты тестирования могут быть полезны для повышения приверженности пациентов к лечению, расшифровке этиологии тромбоза, особенно в молодом возрасти или при атипичной локализации, в рамках семейного консультирования.

Testing for inherited thrombophilia in patients with venous thromboembolism is one of the most common genetic testing options prescribed by clinicians. Despite the large evidence base for the relationship of hereditary hemostasis disorders with the risk of venous thrombosis, most patients should not be tested. Performing tests in the acute phase of thrombosis or during anticoagulant therapy leads to erroneous results. The choice of anticoagulant therapy regimen and its duration are not specified by the presence of hereditary thrombophilia. The test results can be useful for increasing medication adherence of patient, determining the cause of thrombosis, especially at a young age or in atypical localization.

венозные тромбоэмболические осложнениянаследственные тромбофилииантикоагулянтыvenous thromboembolisminherited thrombophiliaanticoagulantsReferencesStevens SM, Woller SC, Bauer KA, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016;41(1):154-64. doi:10.1007/s11239-015-1316-1.Stevens SM, Woller SC, Bauer KA, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016;41(1):154-64. doi:10.1007/s11239-015-1316-1.Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405.Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405.Bockiria LA, Zatevakhin II, Kirienko AI, et al. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications. Phlebology. 2015;4(2):1-52 (in Russ) Бокерия ЛА, Затевахин ИИ, Кириенко АИ, и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология. 2015;4(2):1-52.Bockiria LA, Zatevakhin II, Kirienko AI, et al. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications. Phlebology. 2015;4(2):1-52 (in Russ).Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. 2013;15(2):153-56. doi:10.1038/gim.2012.165.Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. 2013;15(2):153-56. doi:10.1038/gim.2012.165.Zöller B, Li X, Ohlsson H, et al. Family history of venous thromboembolism as a risk factor and genetic research tool. Thromb Haemost. 2015;114(5):890-900. doi:10.1160/TH15-04-0306.Zöller B, Li X, Ohlsson H, et al. Family history of venous thromboembolism as a risk factor and genetic research tool. Thromb Haemost. 2015;114(5):890-900. doi:10.1160/TH15-04-0306.Momot AP. The problem of thrombophilia in clinical practice. Russian Journal of Pediatric Hematology and Oncology. 2015;2(1):36-48. (In Russ.) Момот АП. Проблема тромбофилии в клинической практике. Российский журнал детской гематологии и онкологии. 2015;2(1):36-48. https://doi.org/10.17650/2311-1267-2015-1-36-48.Momot AP. The problem of thrombophilia in clinical practice. Russian Journal of Pediatric Hematology and Oncology. 2015;2(1):36-48. (In Russ.)Lee EJ, Dykas DJ, Leavitt AD, et al. Whole-exome sequencing in evaluation of patients with venous thromboembolism. Blood Adv. 2017;1(16):1224-37. doi:10.1182/bloodadvances.2017005249.Lee EJ, Dykas DJ, Leavitt AD, et al. Whole-exome sequencing in evaluation of patients with venous thromboembolism. Blood Adv. 2017;1(16):1224-37. doi:10.1182/bloodadvances.2017005249.Middeldorp S. Is thrombophilia testing useful? Hematology Am Soc Hematol Educ Program. 2011;2011:150-5. doi:10.1182/asheducation-2011.1.150.Middeldorp S. Is thrombophilia testing useful? Hematology Am Soc Hematol Educ Program. 2011;2011:150-5. doi:10.1182/asheducation-2011.1.150.Colucci G, Tsakiris DA. Thrombophilia screening revisited: an issue of personalized medicine. J Thromb Thrombolysis. 2020;49(4):618-29. doi:10.1007/s11239-020-02090-y.Colucci G, Tsakiris DA. Thrombophilia screening revisited: an issue of personalized medicine. J Thromb Thrombolysis. 2020;49(4):618-29. doi:10.1007/s11239-020-02090-y.Mannucci PM, Franchini M. Classic thrombophilic gene variants. Thromb Haemost. 2015;114(5):885-9. doi:10.1160/TH15-02-0141.Mannucci PM, Franchini M. Classic thrombophilic gene variants. Thromb Haemost. 2015;114(5):885-9. doi:10.1160/TH15-02-0141.Kozak PM, Xu M, Farber-Eger E, et al. Discretionary Thrombophilia Test Acquisition and Outcomes in Patients With Venous Thromboembolism in a Real-World Clinical Setting. J Am Heart Assoc. 2019;8(22):e013395. doi:10.1161/JAHA.119.013395.Kozak PM, Xu M, Farber-Eger E, et al. Discretionary Thrombophilia Test Acquisition and Outcomes in Patients With Venous Thromboembolism in a Real-World Clinical Setting. J Am Heart Assoc. 2019;8(22):e013395. doi:10.1161/JAHA.119.013395.Favaloro EJ. The futility of thrombophilia testing. Clin Chem Lab Med. 2014;52(4):499-503. doi:10.1515/cclm-2013-0560.Favaloro EJ. The futility of thrombophilia testing. Clin Chem Lab Med. 2014;52(4):499-503. doi:10.1515/cclm-2013-0560.Middeldorp S. Inherited thrombophilia: a double-edged sword. Hematology Am Soc Hematol Educ Program. 2016;2016(1):1-9. doi:10.1182/asheducation-2016.1.1.Middeldorp S. Inherited thrombophilia: a double-edged sword. Hematology Am Soc Hematol Educ Program. 2016;2016(1):1-9. doi:10.1182/asheducation-2016.1.1.Downes K, Megy K, Duarte D, et al. Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. Blood. 2019;134(23):2082-91. doi:10.1182/blood.2018891192.Downes K, Megy K, Duarte D, et al. Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. Blood. 2019;134(23):2082-91. doi:10.1182/blood.2018891192.Trégouët DA, Morange PE. What is currently known about the genetics of venous thromboembolism at the dawn of next generation sequencing technologies. Br J Haematol. 2018;180(3):335-45. doi:10.1111/bjh.15004.Trégouët DA, Morange PE. What is currently known about the genetics of venous thromboembolism at the dawn of next generation sequencing technologies. Br J Haematol. 2018;180(3):335-45. doi:10.1111/bjh.15004.Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365-71. doi:10.1182/blood-2018-04-848333.Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365-71. doi:10.1182/blood-2018-04-848333.Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. London: National Institute for Health and Care Excellence (UK); 2020 Mar 26. PMID: 32374563, https://www.nice.org.uk/guidance/ng158Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. London: National Institute for Health and Care Excellence (UK); 2020 Mar 26. PMID: 32374563, https://www.nice.org.uk/guidance/ng158Cook RM, Rondina MT, Horton DJ. Rivaroxaban for the Long-term Treatment of Spontaneous Ovarian Vein Thrombosis Caused by Factor V Leiden Homozygosity. Ann Pharmacother. 2014;48(8):1055-60. doi:10.1177/1060028014533304.Cook RM, Rondina MT, Horton DJ. Rivaroxaban for the Long-term Treatment of Spontaneous Ovarian Vein Thrombosis Caused by Factor V Leiden Homozygosity. Ann Pharmacother. 2014;48(8):1055-60. doi:10.1177/1060028014533304.Jehangir W, Enakuaa S, Udezi V, et al. Treatment for Factor V Leiden, Stuck Between a Rock and a Hard Place: A Case Report and Review of Literature. Journal of Hematology. 2014;3(2):43-5. https://thejh.org/index.php/jh/article/view/149/103Jehangir W, Enakuaa S, Udezi V, et al. Treatment for Factor V Leiden, Stuck Between a Rock and a Hard Place: A Case Report and Review of Literature. Journal of Hematology. 2014;3(2):43-5. https://thejh.org/index.php/jh/article/view/149/103Hermans C, Eeckhoudt S, Lambert C. Dabigatran etexilate (Pradaxa®) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency. Thromb Haemost. 2012;107(6):1189-91. doi:10.1160/TH11-11-0788.Hermans C, Eeckhoudt S, Lambert C. Dabigatran etexilate (Pradaxa®) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency. Thromb Haemost. 2012;107(6):1189-91. doi:10.1160/TH11-11-0788.Martinelli I, Bucciarelli P, Artoni A, et al. Anticoagulant treatment with rivaroxaban in severe protein S deficiency. Pediatrics. 2013;132(5):e1435-e1439. doi:10.1542/peds.2013-1156.Martinelli I, Bucciarelli P, Artoni A, et al. Anticoagulant treatment with rivaroxaban in severe protein S deficiency. Pediatrics. 2013;132(5):e1435-e1439. doi:10.1542/peds.2013-1156.Wypasek E, Potaczek DP, Alhenc-Gelas M et al. PROS1 mutations associated with protein S deficiency in Polish patients with residual vein obstruction on rivaroxaban therapy. Thromb Res. 2014;134(1):199-201. doi:10.1016/j.thromres.2014.01.023.Wypasek E, Potaczek DP, Alhenc-Gelas M et al. PROS1 mutations associated with protein S deficiency in Polish patients with residual vein obstruction on rivaroxaban therapy. Thromb Res. 2014;134(1):199-201. doi:10.1016/j.thromres.2014.01.023.Tàssies D, García de Frutos P. Protein S deficiency and novel oral anticoagulants: an intriguing case. Thromb Res. 2014;134(1):1-2. doi:10.1016/j.thromres.2014.03.008.Tàssies D, García de Frutos P. Protein S deficiency and novel oral anticoagulants: an intriguing case. Thromb Res. 2014;134(1):1-2. doi:10.1016/j.thromres.2014.03.008.Bertoletti L, Benhamou Y, Béjot Y, et al. Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review. Blood Rev. 2018;32(4):272-9. doi:10.1016/j.blre.2018.01.002.Bertoletti L, Benhamou Y, Béjot Y, et al. Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review. Blood Rev. 2018;32(4):272-9. doi:10.1016/j.blre.2018.01.002.Baglin T, Luddington R, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362(9383):523-6. doi:10.1016/S0140-6736(03)14111-6.Baglin T, Luddington R, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362(9383):523-6. doi:10.1016/S0140-6736(03)14111-6.Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293(19):2352-61. doi:10.1001/jama.293.19.2352.Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293(19):2352-61. doi:10.1001/jama.293.19.2352.Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report [published correction appears in Chest. 2016 Oct;150(4):988]. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026.Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report [published correction appears in Chest. 2016 Oct;150(4):988]. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026.Connors JM. Thrombophilia Testing and Venous Thrombosis. N Engl J Med. 2017;377(12):1177-87. doi:10.1056/NEJMra1700365.Connors JM. Thrombophilia Testing and Venous Thrombosis. N Engl J Med. 2017;377(12):1177-87. doi:10.1056/NEJMra1700365.Tait C, Baglin T, Watson H, et al. Guidelines on the investigation and management of venous thrombosis at unusual sites. Br J Haematol. 2012;159(1):28-38. doi:10.1111/j.1365-2141.2012.09249.x.Tait C, Baglin T, Watson H, et al. Guidelines on the investigation and management of venous thrombosis at unusual sites. Br J Haematol. 2012;159(1):28-38. doi:10.1111/j.1365-2141.2012.09249.x.

The authors declare that there are no conflicts of interest present.